DrugPatentWatch Database Preview
VIBATIV Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Vibativ, and what generic alternatives are available?
This drug has one hundred and twenty-four patent family members in thirty-five countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
Summary for VIBATIV
| International Patents: | 124 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 4 |
| Clinical Trials: | 13 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIBATIV |
| DailyMed Link: | VIBATIV at DailyMed |
Generic Entry Opportunity Date for VIBATIV
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VIBATIV
| Ingredient-type | Lipoglycopeptides |
| Drug Class | Lipoglycopeptide Antibacterial |
Synonyms for VIBATIV
| 0701472ZG0 |
| 372151-71-8 |
| 560130-42-9 |
| AC1MIWRX |
| AM006875 |
| Arbelic |
| CHEBI:71226 |
| CHEBI:71229 |
| CHEMBL3301680 |
| CHEMBL507870 |
| D02IJB |
| D06057 |
| D0B9JO |
| DB06402 |
| HSDB 8194 |
| LS-192933 |
| N(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin |
| SCHEMBL8287015 |
| SIB-1533A |
| T-1455 |
| Td 6424 |
| TD-6424 |
| Telavancin |
| Telavancin [INN] |
| Telavancin HCl |
| Telavancin Hydrochloride |
| Telavancin hydrochloride (USAN) |
| Telavancin hydrochloride [USAN] |
| Telavancin, Antibiotic for Culture Media Use Only |
| telavancina |
| telavancine |
| telavancinum |
| UNII-0701472ZG0 |
| UNII-XK134822Z0 |
| Vancomycin, N3'-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride |
| Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)- |
| Vibativ (TN) |
| XK134822Z0 |
US Patents and Regulatory Information for VIBATIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma | VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Theravance Biopharma | VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Theravance Biopharma | VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Theravance Biopharma | VIBATIV | telavancin hydrochloride | POWDER;IV (INFUSION) | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for VIBATIV
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,157,554 | Glycopeptide carboxy-saccharide derivatives | ➤ Sign Up |
| 6,872,804 | Glycopeptide disulfide and thioester derivatives | ➤ Sign Up |
| 6,887,976 | Glycopeptide phosphonate derivatives | ➤ Sign Up |
| 6,620,781 | Glycopeptide carboxy-saccharide derivatives | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for VIBATIV
Supplementary Protection Certificates for VIBATIV
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2011 00033 | Denmark | ➤ Sign Up | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| 2011100062 | Germany | ➤ Sign Up | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| C/GB11/056 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906 |
| C0051 | France | ➤ Sign Up | PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
